Abstract
Background. The main factors that increase the risk of cardiovascular accidents and mortality among patients with COVID-19 include hyperglycemia, arterial hypertension and dyslipidemia. Therefore, all patients with COVID-19 and metabolic syndrome should receive antihypertensive (AHT), hypolipidemic (GLT) and hypoglycemic therapy (GGT). Currently, there is a limited number of studies regarding the effectiveness and safety of this therapy in patients with COVID-19.
Aim. Evaluate the clinical outcomes of patients with COVID-19, depending on the recipient of AHT, GLT and GGT.
Materials and methods. A retrospective analysis of the clinical outcomes "discharged/died" of 1753 patients with COVID-19 was carried out depending on the received AHT, GLT and GGT.
Results. A significant reduction in the risk of mortality among patients with COVID-19 was observed during therapy with angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers ACE inhibitors/ARBs (OR 0.39, 95% CI 0.210.72; p0.05) and b-adrenergic blockers b-AB (OR 0.53, 95% CI 0.281; p0.05). At the same time, against the background of therapy with ACE inhibitors/ARBs and b-ABs, the chance of mortality decreased more significantly among patients with type 2 diabetes mellitus (T2DM) compared with patients without T2DM. Diuretic therapy was associated with a 3-fold increase in the chances of death: OR 3.33, 95% CI 1.884.79; p0.05. Statin therapy did not affect clinical outcomes in COVID-19 patients. On the background of therapy with oral hypoglycemic drugs, the risk of mortality decreased 5-fold (OR 0.19, 95% CI 0.070.54; p0.05). Against the background of insulin therapy, there was an increase in mortality risk by 2.8 times (OR 2.81, 95% CI 1.55.29; p0.05).
Conclusion. A significant reduction in mortality among patients with COVID-19 was observed during therapy with ACEI/ARB, b-AB, and oral hypoglycemic therapy. Increased risk of death was associated with insulin therapy and diuretic therapy.
Subject
General Medicine,Endocrinology, Diabetes and Metabolism,History,Family Practice
Reference36 articles.
1. Авдеев С.Н., Адамян Л.В., Алексеева Е.И., и др. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Министерство здравоохранения Российской Федерации. Версия 7. 03.06.2020 [Avdeev SN, Adamyan LV, Alekseeva EI, et al. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Ministry of Health of the Russian Federation. Version 7. 03.06.2020 (in Russian)].
2. Clinical Characteristics of Coronavirus Disease 2019 in China
3. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China
4. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis
5. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China